Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




DNA Sudoku: Math Puzzle Logic Used to Enhance Genome Sequencing Capability

By LabMedica International staff writers
Posted on 23 Jul 2009
A popular math-based game may now be poised to transform the fast-changing world of genome sequencing and the field of medical genetics, suggests a team of scientists. More...
Combining a 2,000-year-old Chinese math theorem with concepts from cryptology, the scientists have devised "DNA Sudoku.” The strategy allows tens of thousands of DNA samples to be combined, and their sequences--the order in which the letters of the DNA alphabet (A, T, G, and C) line up in the genome--to be determined all at once.

This achievement is in stark contrast to past applications that allowed only a single DNA sample to be sequenced at a time. It also significantly improves upon current approaches that, at best, can combine hundreds of samples for sequencing. "In theory, it is possible to use the Sudoku method to sequence more than a hundred thousand DNA samples,” said Cold Spring Harbor Laboratory (CSHL; Cold Spring Harbor, NY, USA) professor Gregory Hannon, Ph.D., a genomics expert, and leader of the team that invented the Sudoku approach. At that level of efficiency, it has the potential to greatly reduce costs. A sequencing project that costs upwards of US$10 million using conventional methods may be accomplished for $50,000 to $80,000 using DNA Sudoku, he estimated.

Originally devised to overcome a sequencing limitation that plagued one of the Hannon lab's research projects, the new method has tremendous potential for clinical applications. It can be utilized, according to Dr. Hannon, to analyze specific regions of the genomes of a large population and identify individuals who carry mutations that cause genetic diseases--a process known as genotyping.

The CSHL team has already begun to explore this possibility via collaboration with Dor Yeshorim (New York, NY, USA), an organization that has collected DNA from thousands of members of orthodox Jewish communities. The organization's aim is to prevent genetic diseases such as Tay-Sachs or cystic fibrosis that occur frequently within specific ethnic populations. The new method will now allow the many thousands of DNA samples gathered by Dor Yeshorim to be processed and sequenced in a single time-saving and cost-effective experiment, which should identify individuals who carry disease-causing mutations.

The mixing together and simultaneous sequencing of a massive number of DNA samples is known as multiplexing. In earlier multiplexing approaches, scientists first tagged each sample with a barcode--a short string of DNA letters known as oligonucleotides--before mixing it with other samples that also had unique tags. After the sample mix had been sequenced, scientists could use the barcode tags on the resulting sequences as identification markers and thus tell which sequence belonged to which sample.

"But this approach is very limiting,” explained Dr. Yaniv Erlich, a graduate student in the Hannon laboratory and first author on the article. "It's time-consuming and costly to have to design a unique barcode for each sample prior to sequencing, especially if the number of samples runs in the thousands.”

In order to circumvent this limitation, Dr. Erlich and others in the Hannon lab came up with the plan of mixing the samples in specific patterns, thereby creating pools of samples. Moreover, instead of tagging the individual samples within each pool, the scientists tagged each pool as a whole with one barcode. "Since we know which pool contains which samples, we can link a sequence to an individual sample with high confidence,” said Dr. Erlich.

The key to the researchers development is the pooling strategy, which is based on the 2,000-year-old Chinese remainder theorem. "It minimizes the number of pools and the amount of sequencing,” stated Dr. Hannon of their method, which they dubbed DNA Sudoku because of its similarity to the logic and combinatorial number-placement rules used in the popular game.

The technique, which the CSHL team has patented, is currently best suited for genotype analyses that require only short segments of an individual's genome to be sequenced to find out if the individual is carrying a specific variant of a gene or a rare mutation. But as sequencing technologies improve and researchers gain the ability to generate sequences for longer segments of the genome, Dr. Hannon foresees wider clinical applications for their method such as human leukocyte antigen (HLA) typing, already an important diagnostic tool for autoimmune diseases, cancer, and for predicting the risk of organ transplantation.

The report was published in the July 1, 2009, issue of the journal Genome Research.

Related Links:

Cold Spring Harbor Laboratory
Dor Yeshorim




Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Gold Member
Automatic Hematology Analyzer
CF9600
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Molecular Diagnostics

view channel
Image Credit: Shutterstock

Lung Cancer Atlas Reveals Cellular Patterns Associated With Patient Prognosis

Lung cancer is a leading cause of cancer-related death worldwide and is characterized by substantial cellular heterogeneity. Even within a single tumor, cancer cells can vary in aggressiveness, while immune,... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.